SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma gets tentative nod from US FDA for HIV-1 drug

28 Jun 2013 Evaluate

Aurobindo Pharma has received the tentative approval to manufacture and market Efavirenz+Lamivudine+Tenofovir Disoproxil Fumarate Tablets, 600mg/ 300mg/ 300mg from the US Food & Drug Administration (USFDA). The New Drug Application (NDA) 22-343 provides for the use of these tablets alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and adolescents aged more than 16 years of age and weighing at-least 40 kg.

This NDA was reviewed under the President’s Emergency Plan for AIDS Relief (PEPFAR). The estimated ARV Access Market (Emerging Markets) for the product was $120 million last year and expected to record strong growth in the coming year.

The company now has a total of 191 ANDA approvals (163 Final approvals including 4 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA. Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

 

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×